Bio

With more than 22 years in practice, Jonn Beeson has advised on M&A transactions with an aggregate value in excess of $225 billion. His practice focuses on mergers and acquisitions, divestitures, takeovers, capital raising, securities transactions, and corporate governance issues. Jonn represents large publicly traded corporations, middle market private companies, and start-up companies and is most active in the life sciences (including pharmaceuticals, medical devices, and biologics), technology, and software industries. Jonn regularly represents clients on complex strategic transactional and corporate governance matters. His M&A experience includes public company mergers and tender offers, private company acquisitions and divestitures, hostile takeovers, multifaceted cross-border transactions, and transactions involving SEC-registered contingent value rights and earn-outs. Jonn has a particular focus on Asia/U.S. cross-border transactions. He also advises clients in connection with structured options to purchase entities or to purchase or license assets, including significant intellectual property. Jonn's capital markets experience includes initial public offerings, secondary offerings, and venture capital investment transactions. He also serves as a trusted advisor to publicly traded companies in connection with their public company reporting obligations. Jonn's current and prior representations include industry and research leaders such as Abbott Laboratories, AbbVie, Allergan, Astellas Pharma, BioMarin Pharmaceutical, Celgene, City of Hope, Furukawa Electric Co., Linear Technology, NVIDIA, Oclaro, SAP AG, Skyworks, Sumitomo Dainippon Pharma Co., Terumo Corporation, and Ultragenyx. He is a frequent lecturer and author on mergers and acquisitions, spin-offs, and corporate governance issues and has been recognized by BTI Consulting as a client service all-star and Best Lawyers in America (including 2016 M&A lawyer of the year for Orange County, California).